Recombinant Human EPO protein,Fc-tagged
Cat.No. : | EPO-97H |
Product Overview : | Recombinant Human EPO alpha protein was expressed in CHO cells with Fc tag. |
- Specification
- Gene Information
- Related Products
Description : | Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal failure as well as for anemia of AZT treated AIDS patients. |
Source : | CHO |
Species : | Human |
Tag : | Fc |
Form : | Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH 7.4. |
Bio-activity : | Fully biologically active when compared to standard. The Specific Activity was measured by the stimulation of reticulocyte production in normocyth-aemic mice and is no less than 5.0 × 10⁵ IU/mg. |
Molecular Mass : | Recombinant Human EPO/Fc produced in CHO is a dimeric, glycosylated, polypeptide chain consisting of two mature human EPO molecules linked to the Fc portion of human IgG1. The Fc component contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 140 kDa in non-reducing SDS-PAGE. |
Endotoxin : | Less than 1 EU/μg of rHuEPO-Fc a as determined by LAL method. |
Purity : | >98% by SDS-PAGE and HPLC analysis. |
Storage : | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 centigrade as supplied. 1 month, 2 to 8 centigrade under sterile conditions after reconstitution. 3 months, -20 to -70 centigrade under sterile conditions after reconstitution. |
Reconstitution : | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤-20 centigrade. Further dilutions should be made in appropriate buffered solutions. |
Gene Name : | EPO |
Official Symbol : | EPO |
Synonyms : | EPO; erythropoietin; EP; epoetin; MVCD2; MGC138142; |
Gene ID : | 2056 |
mRNA Refseq : | NM_000799 |
Protein Refseq : | NP_000790 |
MIM : | 133170 |
UniProt ID : | P01588 |
Products Types
◆ Recombinant Protein | ||
Epo-1848R | Recombinant Rat Epo Protein | +Inquiry |
Epo-4376M | Recombinant Mouse Epo Protein | +Inquiry |
EPO-1203P | Recombinant Pig EPO Protein, His-tagged | +Inquiry |
EPO-08H | Active Recombinant Human EPO Protein, Animal Free | +Inquiry |
Epo-10549M | Recombinant Mouse Epo Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
EPO-592RCL | Recombinant Rat EPO cell lysate | +Inquiry |
EPO-1450MCL | Recombinant Mouse EPO cell lysate | +Inquiry |
◆ Assay kits | ||
Kit-0327 | Eosinophil Peroxidase Fluorometric Detection Kit | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionEPO protein can promote the renewal and repair of heart blood vessels, and has the effect of protecting the heart from ischemia-reperfusion damage.
By binding to receptors, EPO proteins activate signaling pathways that promote the proliferation and differentiation of hematopoietic stem cells in bone marrow into erythrocytes.
EPO protein can be used by injection or oral, and the specific method and dosage need to be determined according to the condition and the doctor's advice.
The study of EPO protein helps to understand the regulatory mechanism of erythropoiesis and provides new ideas and methods for the treatment of anemia, such as developing more effective EPO protein analogues or improving existing treatment regimens.
This protein stimulates the bone marrow to produce more red blood cells, thereby increasing hemoglobin levels and treating anemia.
In kidney disease, due to impaired kidney function, the production of EPO protein decreases, leading to anemia. Supplementation with exogenous EPO protein can help correct anemia caused by kidney problems.
Customer Reviews (3)
Write a reviewStability is truly remarkable, can maintain its activity even under extreme conditions.
Can catalyze reactions even under extreme conditions.
This protein's repeatability is truly exceptional, consistently delivering reliable results even under challenging conditions.
Ask a Question for All EPO Products
Required fields are marked with *
My Review for All EPO Products
Required fields are marked with *
Inquiry Basket